Skip to main content
Premium Trial:

Request an Annual Quote

PPD Discovery to License Affymetrix Chips and Software

NEW YORK, Jan 31 - PPD Discovery said Wednesday it would license Affymetrix' GeneChip DNA microarrays as well as its array instrumentation and analysis software.

The company will use the Affymetrix products in its functional genomics-based drug target validation efforts. PPD Discovery, a subsidiary of drug discovery and development services company PPD, uses its genomics platform to isolate gene inhibitors for cells, in order to identify novel therapeutic targets and gain insights on genome function.

" Affymetrix' technology adds a new dimension to our functional genomics program,"  Tanya Holzmayer, vice president of genomics at PPD Discovery, said in a statement. " We have evaluated a variety of expression profiling technologies and believe that Affymetrix' GeneChip technology will considerably expedite our process of target validation."

The companies did not disclose the financial terms of the agreement.

Some of Affymetrix’s other GeneChip Platform and service access customers have included Astra, Bristol-Myers Squibb, DNAX, Eli Lilly, Human Genome Sciences, Genecor, Glaxo Wellcome, Merck, Millennium, Novartis, Pharmacia & Upjohn, Pioneer, Research Genetics, Rosetta, Sanofi Recherche, Schering, and Tularik.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.